These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34902571)

  • 1. Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations.
    Arvind A; Joshi S; Zaki T; Burkholder D; Parikh ND; Singal AG;
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1091-1093.e3. PubMed ID: 34902571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes of Patients With Suspicious (LI-RADS 4) Liver Observations.
    Onyirioha K; Joshi S; Burkholder D; Yekkaluri S; Parikh ND; Singal AG;
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1649-1651.e2. PubMed ID: 35413448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of LI-RADS 3 or 4 Observations with Histopathologic Diagnosis in Patients with Cirrhosis.
    Dunn C; Lin B; Rich NE; Patel MS; Gopal P; Singal AG
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1351-1353.e2. PubMed ID: 35307596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and clinical significance of discordant LI-RADS
    Yokoo T; Singal AG; Diaz de Leon A; Ananthakrishnan L; Fetzer DT; Pedrosa I; Khatri G
    Abdom Radiol (NY); 2020 Jan; 45(1):177-187. PubMed ID: 31342103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cirrhotic liver: What's that nodule? The LI-RADS approach.
    Shah A; Tang A; Santillan C; Sirlin C
    J Magn Reson Imaging; 2016 Feb; 43(2):281-94. PubMed ID: 25996905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
    Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
    World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma.
    Shahbazian H; Birnbaum J; Burns PJ; Shabanan SH; Kanmaniraja D; Reinus J; Kamel I; Sirlin CB; Chernyak V
    Abdom Radiol (NY); 2023 Dec; 48(12):3696-3702. PubMed ID: 37725110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients.
    Wu Y; Chen Y; Wei L; Ding Z; Zhao S; Bao S; Tang J; Li H; Liu J; Zhu S
    J Cancer Res Ther; 2024 Aug; 20(4):1274-1283. PubMed ID: 38958652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
    Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
    Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of CEUS on non-characterizable observations and observations with intermediate probability of malignancy on CT/MRI in patients at risk for HCC.
    Kono Y; Piscaglia F; Wilson SR; Medellin A; Rodgers SK; Planz V; Kamaya A; Fetzer DT; Berzigotti A; Sidhu PS; Wessner CE; Bradigan K; Kuon Yeng Escalante CM; Siu Xiao T; Eisenbrey JR; Forsberg F; Lyshchik A;
    Abdom Radiol (NY); 2024 Aug; 49(8):2639-2649. PubMed ID: 38860996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
    Kim YY; An C; Kim S; Kim MJ
    Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review.
    Kanneganti M; Marrero JA; Parikh ND; Kanwal F; Yokoo T; Mendiratta-Lala M; Rich NE; Gopal P; Singal AG
    Liver Transpl; 2022 Dec; 28(12):1865-1875. PubMed ID: 35980600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-contrast abbreviated MRI for the detection of hepatocellular carcinoma in patients with Liver Imaging Reporting and Data System LR-3 and LR-4 observations in MRI.
    Maung ST; Tanpowpong N; Satja M; Treeprasertsuk S; Chaiteerakij R
    Br J Radiol; 2024 Oct; 97(1162):1671-1682. PubMed ID: 39115388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review.
    van der Pol CB; Lim CS; Sirlin CB; McGrath TA; Salameh JP; Bashir MR; Tang A; Singal AG; Costa AF; Fowler K; McInnes MDF
    Gastroenterology; 2019 Mar; 156(4):976-986. PubMed ID: 30445016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Imaging Reporting and Data System: Review of Pros and Cons.
    Terzi E; Ayuso C; Piscaglia F; Bruix J
    Semin Liver Dis; 2022 Feb; 42(1):104-111. PubMed ID: 34298576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm.
    Ronot M; Fouque O; Esvan M; Lebigot J; Aubé C; Vilgrain V
    J Hepatol; 2018 Apr; 68(4):715-723. PubMed ID: 29274407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.